Agamon is redefining patient management in radiology, replacing manual follow-up processes with smart AI automation. The Agamon Platform provides an end-to-end solution for imaging follow-up management. Deployed in some of the leading healthcare organizations in the US it demonstrated increased patient adherence, reduced health system liability, and generated new revenue streams for health systems and radiology practices.

Biobeat’s remote patient monitoring health-AI platform includes a wearable monitor which utilizes a photoplethysmography-based (PPG) sensor to continuously provide accurate patient readings of 13 health parameters, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, and more. Aggregated patient health data is viewed by medical staff via Biobeat’s secure cloud-based patient management platform, which utilizes a real-time early warning score system that incorporates advanced AI-based algorithms to provide alerts on patient health status and potential deterioration. Biobeat’s wearable devices are the first devices to be FDA-Cleared for cuffless non-invasive blood pressure monitoring and are also CE Mark certified.

As the pioneer in remote patient management Commwell has taken its 35+ years of experience working with physicians and their patients remotely and developed a holistic constellation of products. Health eCare is the only remote patient management platform of its kind that enables complete customization and personalization in accordance with the needs of the customer. The platform records and manages essential patient conditions according to clinical protocols and integrates with the Commwell proprietary measuring solutions along with third party diagnostic devices. Physioglove is the only 12 lead ECG device for self-use by patients at home. Sentinel is a 2-channel wearable continuous 3-in-1 arrythmia monitor: Event, Telemetry and Holter.

Predicta Med's platform aims to improve the quality of care for patients with immune-related conditions and reduce healthcare costs by enabling providers to detect these diseases months to years earlier than the current standard of care. The platform facilitates identification of individuals with undiagnosed immune-related conditions, enabling targeted interventions earlier in disease course to help prevent disease deterioration and complications. To date, the models were trained and validated on more than 6.5M electronical patients records and 1.7M claims records.

TechnoPulm is shifting the Pulmonary Functional test paradigm. By using the Technopulm STS handheld device, Pulmonary Functional Tests can be performed in the community and avoid the need of sending patients to the hospital to By have respiratory disease diagnostics. Technopulm completed the product development with a successful a clinical trial on 161 subjects at Kaplan Hospital, holding granted patents in the US and Europe, completed the quality assurance system that complies with the ISO 13845 standard, and finalized the submission files to the FDA/CE. These days TechnoPulm is conducting a clinical pilot jointly with two leading HMOs in Israel to diagnose lung diseases from the community and is working to create collaborations in the United States and Europe.